# Elypta

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/elypta

- Industry: Medical Devices & Equipment
- Headquarters: Solna, Sweden
- Website: www.elypta.com
- Total disclosed funding: $28M
- Latest round: Series A (Jun 20, 2022)
- Investors on record: 7

## About

Elypta AB specializes in innovative liquid biopsy solutions for early cancer detection, leveraging machine learning algorithms to analyze metabolic biomarkers associated with tumors, ultimately enhancing clinical decision-making.Founded in 2017 in Solna, Sweden, Elypta AB focuses on developing noninvasive cancer diagnostics. The company has secured USD 21.00 mn in a Series A funding round led by Bonnier Capital, with participation from investors such as Chalmers Ventures and Industrifonden. Founded by Francesco Gatto, Elypta has completed 2 deals to date, with the most recent deal occurring on June 20, 2022. The firm operates from its headquarters in Solna, Sweden.Elypta's primary offering is a metabolism-based liquid biopsy aimed at early cancer detection. This innovative approach focuses on measuring the GAGome, a collection of system biomarkers linked to tumor metabolism, analyzed using machine learning algorithms to identify cancer signatures in a noninvasive manner. The service assists healthcare providers in enabling earlier diagnosis and intervention, ultimately aiming to reduce cancer mortality rates. Elypta's solutions are directed towards clinical applications and are positioned to serve hospitals, research institutions, and oncologists across Europe and North America. The company actively seeks partnerships with academia and the industry to further develop companion diagnostics and expand its customer base.Elypta reported revenue of USD 2,474.30 mn for the most recent year 2022. The company generated revenue primarily through partnerships and collaborations with academic institutions and healthcare organizations utilizing its liquid biopsy technology in clinical settings. Transaction structures typically involve agreements where Elypta provides its diagnostic services or products to hospitals and clinics, facilitating early cancer detection. While specific pricing details for each service are not disclosed, various pricing models are offered, including potential subscription or direct-to-clinic arrangements.Elypta plans to utilize the capital raised in the June 2022 Series A funding round, amounting to USD 21.00 mn, to develop and validate blood and urine tests for Multi-Cancer Early Detection (MCED) in adults with no cancer symptoms, as well as for the detection of recurrence in kidney cancer patients. The company aims to expand its market reach, targeting healthcare providers in additional regions across Europe and North America by 2024, further bolstering its role in transforming cancer diagnostics.

## Funding rounds

- Series A, Jun 20, 2022, $21M — Industrifonden, Chalmers Ventures, Bonnier Capital, Norrsken VC, Nina Capital, Navigare Ventures, Hillclimber Holding AB
- Seed, Jan 23, 2020, $6.7M — Industrifonden, Chalmers Ventures, Norrsken VC, Nina Capital

## Investors

- Industrifonden (https://capitalatlas.ai/funds/industrifonden) — Seed, Series A
- Chalmers Ventures (https://capitalatlas.ai/funds/chalmers-ventures) — Seed, Series A
- Norrsken VC (https://capitalatlas.ai/funds/norrsken-vc) — Seed, Series A
- Nina Capital (https://capitalatlas.ai/funds/nina-capital) — Seed, Series A
- Bonnier Capital (https://capitalatlas.ai/funds/bonnier-capital) — Series A
- Navigare Ventures (https://capitalatlas.ai/funds/navigare-ventures) — Series A
- Hillclimber Holding AB — Series A